Drospirenone

• CAT Number: A000572
• CAS Number: 67392-87-4
• Molecular Formula: C24H30O3
• Molecular Weight: 366.49
• Purity: 98%
• Synonyms: (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5′-oxolane]-2′,7-dione
• Target: Estrogen/progestogen Receptor
• Target Protein: P10275
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
• InChI: InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
• InChIKey: METQSPRSQINEEU-HXCATZOESA-N
• SMILES: C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C

Drospirenone（Cat No.:A000572）is a synthetic progestin commonly used in combination oral contraceptives and hormone replacement therapy. It mimics natural progesterone, providing contraceptive effects by inhibiting ovulation and altering the uterine lining to prevent pregnancy. Drospirenone also possesses anti-androgenic and mild diuretic properties, reducing bloating and water retention, making it beneficial for women with hormone-related fluid retention. Additionally, it is used in the management of premenstrual dysphoric disorder (PMDD) and acne. Drospirenone’s unique profile offers a well-tolerated option for women seeking contraception and hormonal balance.

Reference

[1]. Marqueño A, et al. Drospirenone induces the accumulation of triacylglycerides in the fish hepatoma cell line, PLHC-1 [J]. Science of The Total Environment, 2019, 692: 653-659.
[Content Brief]

[2]. Sabouni R, et al. Drospirenone effects on the plasminogen activator system in immortalized human endometrial endothelial cells [J]. Reproductive sciences, 2021, 28: 1974-1980.
[Content Brief]

[3]. Mir A H, et al. Genotoxic effects of drospirenone and ethinylestradiol in human breast cells (in vitro) and bone marrow cells of female mice (in vivo) [J]. Drug and Chemical Toxicology, 2022, 45(4): 1493-1499.
[Content Brief]

[4]. Motivala A, et al. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? [J]. Drugs, 2007, 67: 647-655.
[Content Brief]

[5]. Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54(4): p. 243-51.
[Content Brief]

[6]. Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51(2): p. 99-110.
[Content Brief]

[7]. Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7(1): p. 103-11.
[Content Brief]